Join us at this x-talks hosted webinar and discover outsourcing options for highly potent oral solid dose therapies, and learn how CDMOs can transfer, handle and deliver their product to clinic and to market.
How does a CDMO ensure the successful development and manufacture of breakthrough discoveries? Could drug development projects be translated into safe, effective and accessible drug products for patients, whilst ensuring a greater speed to market for sponsor organizations? In this webinar, the featured speakers share CDMO insights on outsourcing high potent oral solid dose late-stage development.
The development and manufacture of drug products containing highly potent active pharmaceutical ingredients (HPAPIs) is in demand. Recent data suggest that between 2023 and 2030, the small molecule drug discovery market will register a compound annual growth rate (CAGR) of around eight percent. This is particularly relevant in the field of oncology, which accounts for around 35 percent of small molecule drug candidates, around half of which contain HPAPIs.
The development of targeted therapies and precision medicines has revolutionized cancer treatment, resulting in more effective and potentially less toxic therapeutic options for patients. Furthermore, regulatory agencies including the US Food and Drug Administration (FDA) have implemented accelerated approval pathways, fostering innovation and promoting faster commercialization of novel oncology drugs. In this dynamic landscape, the role of CDMOs becomes even more critical.
In this webinar, the speakers will explain what the gold standard is for an outsourcing partner for high potent oral solid dose therapies, the necessary equipment and facilities and how to maintain flexibility in a multi-product facility. They will also discuss a real-world case study, highlighting the importance of selecting the right CDMO for high potent outsourcing.
What You Will Learn:
- What it means to be the gold standard CDMO outsourcing partner today
- The complexities involved with handling highly potent molecules
- The equipment and facilities required to develop, manufacture and scale-up highly potent drug products
- How a multi-product CDMO maintains flexibility for its clients
Join David O’Connell and Lauren Angove-Parry from PCI Pharma Services at this weminar, where we’ll assess the challenges, review key learnings and examine the key considerations you should be implementing to successfully accelerate your journey from Phase I and beyond.
Let’s talk future™
We would love for you to join us for this exciting event – REGISTER NOW
Event: Webinar: CDMO Insights - Outsourcing High Potent Oral Solid Dose Late-Stage Development
Date: 29 June 2023